HCM Risk-SCD score and its relation with functional status and comorbidities in HCM patients

Introduction Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder associated with heart failure, arrhythmias, and an increased risk of sudden cardiac death (SCD). Functional status and the HCM Risk-SCD score are key parameters guiding management. This study assessed the relationship between functional status, comorbidity burden, and the HCM Risk-SCD score in patients with HCM. Material and methods This retrospective single-cohort study included 56 patients with HCM. The HCM Risk-SCD score was calculated according to the 2023 ESC guidelines. Patients were stratified by heart failure symptoms into asymptomatic (NYHA I) and symptomatic (NYHA II–III) groups, and by comorbidity burden into low (0–1) and high (≥2) groups. Assessed comorbidities included systemic hypertension, hyperlipidemia, coronary artery disease, chronic kidney disease, COPD, and type 2 diabetes. Results The median HCM Risk-SCD score was higher in asymptomatic than symptomatic patients (3.46% [IQR 2.38-4.44] vs. 2.07% [IQR 1.17-2.23]; p=0.005). No significant difference was observed between patients with low and high comorbidity burden (1.95% vs. 2.01%; p=0.765), and no correlation was found between the HCM Risk-SCD score and the number of comorbidities (rho=-0.07, p=0.607). Conclusions Asymptomatic patients with HCM had a higher estimated risk of SCD than symptomatic patients. The HCM Risk-SCD score appeared to be independent of comorbidity burden. This shows that HCM individuals with better clinical and functional status may be at higher risk of SCD.

Authors

Institutions

Publication Details

Journal
Annales Academiae Medicae Silesiensis
Published
2026-11-16
DOI
https://doi.org/10.18794/aams/242511
Primary Topic
Cardiomyopathy and Myosin Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

HCM Risk-SCD score and its relation with functional status and comorbidities in HCM patients

Maciej Podolski, Katarzyna Mizia­‐Stec, Zuzanna Niedoba, Julia Nowak et al.
4 links
Annales Academiae Medicae Silesiensis
Cardiomyopathy and Myosin Studies
article

HCM Risk-SCD score and its relation with functional status and comorbidities in HCM patients

Maciej Podolski, Katarzyna Mizia­‐Stec, Zuzanna Niedoba, Julia Nowak, Maria Kaspera, Jakub Kromołowski, Karolina Nogala, Barbara Krywult
article en

Abstract

Introduction Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder associated with heart failure, arrhythmias, and an increased risk of sudden cardiac death (SCD). Functional status and the HCM Risk-SCD score are key parameters guiding management. This study assessed the relationship between functional status, comorbidity burden, and the HCM Risk-SCD score in patients with HCM. Material and methods This retrospective single-cohort study included 56 patients with HCM. The HCM Risk-SCD score was calculated according to the 2023 ESC guidelines. Patients were stratified by heart failure symptoms into asymptomatic (NYHA I) and symptomatic (NYHA II–III) groups, and by comorbidity burden into low (0–1) and high (≥2) groups. Assessed comorbidities included systemic hypertension, hyperlipidemia, coronary artery disease, chronic kidney disease, COPD, and type 2 diabetes. Results The median HCM Risk-SCD score was higher in asymptomatic than symptomatic patients (3.46% [IQR 2.38-4.44] vs. 2.07% [IQR 1.17-2.23]; p=0.005). No significant difference was observed between patients with low and high comorbidity burden (1.95% vs. 2.01%; p=0.765), and no correlation was found between the HCM Risk-SCD score and the number of comorbidities (rho=-0.07, p=0.607). Conclusions Asymptomatic patients with HCM had a higher estimated risk of SCD than symptomatic patients. The HCM Risk-SCD score appeared to be independent of comorbidity burden. This shows that HCM individuals with better clinical and functional status may be at higher risk of SCD.

Annales Academiae Medicae Silesiensis
Medical University of Silesia (PL), ERN GUARD-Heart (NL)
Good health and well-being
Cardiomyopathy and Myosin Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon